Th

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicants: Bandi Parthasaradhi Reddy, et al.

Serial No: 10/571,744

Group Art Unit:

Filed: March 13, 2006

Examiner:

Att. Docket No.: H1089/20032

Confirmation No.:

For:

CRYSTALLINE ALFUZOSIN BASE

IDS CERTIFICATION STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached Form PTO/SB/08a. Unless otherwise indicated herein, one copy of each reference is attached. No copies of U.S. patents or U.S. patent application publications are attached. 37 CFR § 1.98(a)(2)(ii). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the references are prior art with respect to this application.

This Information Disclosure Statement is being filed within three months of the filing date of a national application other than a CPA under 37 CFR § 1.53(d), within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application, before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of an RCE under 37 CFR § 1.114. No certification or fee is required. 37 CFR § 1.97(b).

Application No. 10/571,744 IDS Certification Statement dated September 20, 2006

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.

September 20, 2006

Please charge or credit our Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission.

Robert S. Silver
Registration No. 35,681
Customer No. 03000
(215) 567-2010
Attorneys for Applicant(s)

EXAMINER

Approved for use through 10/31/2002. OMB 0651-0031

Substitute for PTO/SB/O8A (08-00) U.S. Patent and Trademark Office: U.S. DEPART Under the Paperwork Reduction Act of 1995, no persons are required to respond to collection of information unless it contains a valid OMB control number. U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Substitute for Form 1449A/PTO Complete if Known 10/571,744 **Application Number** INFORMATION DISCLOSURE Filing Date March 13, 2006 STATEMENT BY APPLICANT Reddy Bandi Parthasaradhi, First Named Inventor (use as many sheet as necessary) et al. Group Art Unit **Examiner Name Attorney Docket Number** H1089/20032 Sheet of 1 **U.S. PATENT DOCUMENTS** U.S. Patent Document **Date of Publication** Examiner Cite Name of Patentee or Applicant of Cited Document of Cited Document Initials* No. Number Kind Code MM-DD-YYYY (if known) 4,315,007 Phillippe M. Manoury 5,545,738 Borrega, et al. FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Examiner Cite Name of Patentee or Applicant of Cited Document of Cited Document T Kind Code Office Number Initials* No. MM-DD-YYYY (If known) GB 2,231,571 Jozsef Relter, et al. A2 Shriram Narendra Josh WO 2006/090268 Bandi Parthasaradhi Reddy WO **A1** 2006/030449 OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS Cite Examiner Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Initials* No. PCT INTERNATIONAL SEARCH REPORT DATED JUNE 29, 2005, NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION **DATED JUNE 29, 2006** SYNTHESIS AND ANTIHYPERTENSIVE ACTIVITY OF A SERIES OF AMINO-6-7-DIMETHOXYQUINAZOLINE DERIVATIVES, J. ORG. CHEM., 1986, VOL. 29, PAGES 19-25 J. Org. Chem., 1988, 53, pages 983-991.

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED